List of Excipients in Branded Drug CAFCIT

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	CAFCIT	caffeine citrate	0641-6164	CITRIC ACID MONOHYDRATE
Hikma Pharmaceuticals USA Inc	CAFCIT	caffeine citrate	0641-6164	SODIUM CITRATE
Hikma Pharmaceuticals USA Inc	CAFCIT	caffeine citrate	0641-6164	WATER

CAFCIT Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 1, 2026

CAFCIT is a caffeine citrate product for apnea of prematurity. Its commercial position rests on an old active ingredient, a simple aqueous formulation, neonatal dosing convenience, and hospital procurement rather than patent exclusivity. The principal opportunities are generic entry, ready-to-administer neonatal presentations, low-extractables packaging, preservative-free manufacturing, and differentiated supply reliability.

What is CAFCIT and how is it formulated?

CAFCIT contains caffeine citrate, the citrate salt of caffeine, in two sterile dosage forms:

Product	Strength	Route	Labelled caffeine-base equivalent
CAFCIT injection	20 mg/mL caffeine citrate	Intravenous or oral	10 mg/mL caffeine
CAFCIT oral solution	20 mg/mL caffeine citrate	Oral	10 mg/mL caffeine

The product is used to treat apnea of prematurity in neonates. The labeled loading dose is 20 mg/kg caffeine citrate, equivalent to 10 mg/kg caffeine base, followed by a maintenance dose of 5 mg/kg caffeine citrate, equivalent to 2.5 mg/kg caffeine base, once daily. The product is supplied as a sterile, aqueous formulation in single-dose containers. [1]

The formulation is intentionally simple. The U.S. prescribing information identifies caffeine citrate as the active ingredient and lists citric acid anhydrous, sodium citrate dihydrate, and water for injection as inactive ingredients. The formulation uses a citrate buffer system to control pH and maintain chemical stability. [1]

What excipients are used in CAFCIT?

The disclosed excipient system includes:

Excipient	Primary formulation function	Commercial relevance
Citric acid anhydrous	Acid component of citrate buffer; pH adjustment	Influences pH, stability, and injection tolerability
Sodium citrate dihydrate	Buffer component	Controls pH and supports formulation consistency
Water for injection	Sterile vehicle	Determines aseptic-processing and container-closure requirements

The label does not identify preservatives, alcohol, propylene glycol, benzyl alcohol, parabens, or polysorbates. The absence of antimicrobial preservatives is commercially relevant because neonates are a high-sensitivity patient population and many neonatal injectable products are designed for single-dose use.

What excipient strategy is appropriate for CAFCIT generic products?

A generic developer should initially pursue a formulation that is qualitatively and quantitatively close to the reference product. This reduces regulatory, compatibility, and clinical-risk exposure. The most defensible strategy is a citrate-buffered, preservative-free aqueous solution with the same strength and caffeine-base equivalence.

Should a generic use the same citrate buffer?

Yes, unless stability or manufacturing data support an alternative. A citrate buffer provides a direct path to comparative pharmaceutical quality. A materially different buffer, such as phosphate or acetate, could affect pH, precipitation risk, osmolality, extractables, container compatibility, and injection tolerability.

The target formulation should control:

• pH across shelf life;
• caffeine citrate assay and related substances;
• osmolality;
• particulate matter;
• sterility and bacterial endotoxins;
• container-closure integrity;
• visible and subvisible particles;
• adsorption or leaching from the primary container.

A generic applicant does not need to copy every excipient concentration if the product satisfies applicable pharmaceutical-equivalence and quality requirements. In practice, however, a close formulation reduces the number of variables in stability, extractables, and compatibility studies.

Is a preservative-free formulation commercially preferable?

Generally, yes. Preservative-free single-dose packaging is aligned with neonatal practice and reduces concerns associated with benzyl alcohol and other antimicrobial preservatives. A preservative-free product also avoids the need to justify preservative exposure in premature infants.

The tradeoff is operational. The manufacturer must maintain robust aseptic processing, validated sterilization controls, and container-closure integrity. The product cannot rely on multidose antimicrobial protection to compensate for poor handling.

Which packaging materials create differentiation?

The main packaging choices are:

Packaging option	Advantage	Limitation
Glass vial	Established parenteral platform; strong barrier properties	Breakage, delamination risk, manual withdrawal
Polymer vial or ampoule	Lower breakage and lighter logistics	Extractables, permeability, device compatibility
Prefilled syringe	Reduces preparation steps and dosing errors	Higher device-development and combination-product complexity
Unit-dose oral syringe	Improves bedside dosing and administration	Additional packaging and dosing-device validation
Ready-to-use bag	Supports pharmacy and NICU workflow	Larger fill volume and lower flexibility for low-volume doses

The highest-value opportunity is likely a ready-to-administer presentation rather than a novel excipient. Neonatal doses are weight-based and often involve small volumes. A calibrated oral syringe, pharmacy-ready unit dose, or low-volume prefilled presentation can reduce calculation and withdrawal errors.

What patents protect CAFCIT?

CAFCIT has limited apparent patent-based protection because caffeine citrate and the underlying therapeutic use are longstanding. The commercial product’s defensibility is primarily regulatory, manufacturing, quality, and supply-chain based.

The relevant intellectual-property categories are:

1. formulation patents covering buffer composition, pH, concentration, or stability;
2. container-closure patents covering vials, syringes, or unit-dose devices;
3. manufacturing patents covering sterile filling, depyrogenation, or packaging;
4. method-of-use patents covering neonatal apnea treatment or dosing;
5. trademarks and trade dress associated with CAFCIT.

A review of the FDA Orange Book should determine whether the CAFCIT reference listed drug has active patents or exclusivity codes. The FDA label identifies CAFCIT as an approved NDA product, but the formulation disclosed in the label is technically conventional. [1, 2]

What is the Orange Book status of CAFCIT?

CAFCIT is associated with FDA NDA 020793 in FDA drug-product records. [1] The Orange Book should be checked for current patent listings, pediatric exclusivity, and reference-listed-drug status before filing an ANDA. The absence of a patent listing would remove the need for a Paragraph IV certification against an Orange Book patent, although an applicant would still need to address any applicable regulatory exclusivity.

Because Orange Book listings and exclusivity records can change, the legal position should be assessed against the current FDA electronic Orange Book and Drugs@FDA records at filing.

When does CAFCIT lose exclusivity?

CAFCIT is not commercially protected by a modern composition-of-matter patent. The product was approved in 1999, and any ordinary new-drug exclusivity associated with that approval has expired. [1]

Protection category	CAFCIT position
New chemical entity exclusivity	Not applicable to caffeine
Five-year NCE exclusivity	Expired or unavailable
Three-year approval exclusivity	Expired
Orphan-drug exclusivity	Not identified as the core protection
Pediatric exclusivity	Any historical period would have expired
Patent term extension	No commercially relevant active term identified
Regulatory data exclusivity	Expired for the 1999 approval
Trademark protection	Potentially ongoing, but does not block generic approval

The practical result is that generic competition is legally feasible, subject to current Orange Book records and the ANDA pathway.

Are Paragraph IV challenges likely for CAFCIT?

A Paragraph IV challenge is possible only if an unexpired Orange Book-listed patent remains relevant. Given the age of the CAFCIT approval and the conventional formulation, the more likely ANDA pathway would involve a Paragraph III certification if a patent has an expiration date that extends beyond filing, or a Paragraph I/II certification if no relevant patent information is listed.

A Paragraph IV strategy would be commercially attractive only if:

• an active formulation or device patent is listed;
• the reference product has meaningful market share;
• the applicant can establish a credible noninfringement or invalidity position;
• the 180-day generic exclusivity opportunity has material value.

The likely patent risk is lower than the regulatory and commercial execution risk. An ANDA applicant should focus on formulation equivalence, neonatal safety controls, and supply reliability rather than assume a litigation-driven launch.

What litigation and settlement risks affect CAFCIT?

No major, broadly reported CAFCIT patent-litigation campaign is established in the core public record reviewed for this analysis. No settlement-driven generic entry date should be assumed.

Potential disputes could still arise over:

• listed formulation patents;
• device patents for prefilled syringes;
• trade dress or trademark use;
• manufacturing-process patents;
• ANDA labeling and method-of-use carve-outs;
• product liability involving dosing or concentration errors.

A generic product should avoid CAFCIT branding and use a neutral presentation that distinguishes the product from the reference product while preserving clear caffeine citrate labeling.

What FDA regulatory pathway applies to CAFCIT generics?

The principal U.S. pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence or satisfy FDA’s applicable waiver or alternative demonstration requirements. [3]

For an aqueous oral solution, in vivo bioequivalence may be unnecessary if the formulation meets FDA requirements for a biowaiver. For an injectable aqueous solution, the applicant must address pharmaceutical equivalence, sterility, pyrogenicity, inactive ingredients, concentration, route, and container closure. FDA may require additional comparative data depending on formulation and presentation.

The regulatory file should address:

• identical active ingredient strength;
• caffeine citrate-to-caffeine-base conversion;
• pH and osmolality;
• excipient identity and concentration;
• sterility assurance;
• preservative status;
• extractables and leachables;
• photostability;
• in-use stability;
• compatibility with common neonatal administration materials;
• labeling for intravenous and oral use.

What commercial opportunities exist for CAFCIT excipients and dosage forms?

1. Generic sterile aqueous solution

The lowest-risk opportunity is a conventional 20 mg/mL caffeine citrate injection and oral solution. It requires limited formulation novelty and can compete on price, supply, and contract terms.

2. Ready-to-administer neonatal doses

A premeasured oral syringe or pharmacy-prepared unit-dose system can reduce bedside calculations and manipulation. The value proposition is workflow control rather than a new pharmacologic effect.

3. Low-volume delivery systems

Neonatal administration often involves small volumes. A device calibrated for weight-based dosing could reduce withdrawal errors. The development burden includes dose accuracy across the labeled volume range, syringe dead space, plunger performance, and compatibility with the formulation.

4. Hospital-premix or pharmacy-ready supply

Hospitals may value products that reduce compounding steps. A manufacturer could offer unit-dose packaging, barcode-ready labels, and standardized cartons for neonatal intensive-care units.

5. Global formulations

Markets outside the United States may prefer oral drops, multidose bottles, ampoules, or different concentration conventions. Geographic expansion requires review of local pediatric labeling, preservative limits, packaging requirements, and caffeine-base versus caffeine-citrate nomenclature.

6. Supply-chain differentiation

Caffeine citrate is a relatively simple formulation, so supply continuity can be a major purchasing factor. Dual-source API qualification, redundant sterile-filling capacity, and validated alternative packaging could support hospital contracts.

How strong is the CAFCIT patent estate?

The patent estate appears weak relative to products protected by active composition-of-matter, formulation, or device patents. The formulation is based on common excipients and an established buffer system. The strongest defensible assets are likely to be:

• process controls for sterile manufacture;
• container-closure and device configurations;
• proprietary unit-dose packaging;
• manufacturing know-how;
• brand recognition;
• hospital purchasing relationships.

These assets can support commercial differentiation but generally do not prevent ANDA competition.

Does biosimilar risk apply to CAFCIT?

No. CAFCIT is a small-molecule caffeine citrate product, not a biologic. Biosimilar approval under the Public Health Service Act is therefore not the relevant competitive pathway. The principal threat is conventional generic competition through ANDAs. [3]

How does CAFCIT compare with competing caffeine citrate products?

Factor	CAFCIT	Generic caffeine citrate opportunity
Active ingredient	Caffeine citrate	Same
Primary use	Apnea of prematurity	Same
Formulation	Preservative-free aqueous solution	Can closely match
Patent barrier	Limited apparent protection	Low patent-entry barrier
Regulatory pathway	NDA reference product	ANDA
Differentiation	Brand, availability, packaging	Price, supply, device, workflow
Biosimilar risk	Not applicable	Not applicable
Main commercial risk	Generic erosion and shortages	Manufacturing reliability and contracting

What generic launch scenarios exist?

Base case

One or more ANDA products enter with the same 20 mg/mL strength and conventional vial or oral-solution packaging. Price competition develops quickly because formulation complexity is low.

Premium generic case

A supplier launches preservative-free, unit-dose oral syringes or prefilled presentations. The product captures institutional accounts despite a moderate price premium.

Supply-constrained case

A shortage or manufacturing interruption at the reference or incumbent generic supplier allows a reliable entrant to gain hospital contracts. Sterile capacity and API continuity become more valuable than formulation novelty.

Litigation-delayed case

An active listed formulation or device patent is identified and challenged. Entry timing depends on certification, litigation, and any settlement. No such delay should be presumed without a current Orange Book review.

Key Takeaways

• CAFCIT is a 20 mg/mL caffeine citrate product used for apnea of prematurity.
• The disclosed excipient system is a simple citrate-buffered aqueous formulation using citric acid, sodium citrate, and water for injection.
• A preservative-free formulation is commercially and clinically appropriate for neonatal use.
• CAFCIT’s main protection is not an apparent active patent estate but brand, manufacturing quality, hospital relationships, and supply reliability.
• The relevant competitive pathway is an ANDA, not a biosimilar application.
• The strongest commercial opportunities are generic sterile solution, unit-dose oral delivery, prefilled devices, and pharmacy-ready neonatal packaging.
• The most important diligence items are current Orange Book listings, NDA records, formulation equivalence, container compatibility, and sterile-manufacturing capacity.

FAQs

Is caffeine citrate the same as caffeine base?

No. Caffeine citrate is a salt containing caffeine and citric acid. CAFCIT’s labeled 20 mg/mL caffeine citrate concentration is equivalent to 10 mg/mL caffeine base.

Can caffeine citrate be reformulated with a different buffer?

Potentially, but a different buffer can affect pH, stability, osmolality, compatibility, and regulatory comparability. A citrate-buffered formulation is the lower-risk development strategy.

Is CAFCIT available as a tablet or capsule?

CAFCIT is marketed as an injectable and oral solution product for neonatal use. Tablet or capsule development would not address the same neonatal administration requirements.

What is the most valuable excipient innovation for caffeine citrate?

The highest commercial value is unlikely to come from a new excipient. It is more likely to come from a stable preservative-free formulation combined with unit-dose, syringe-based, or ready-to-administer packaging.

Can a generic caffeine citrate product use the CAFCIT name?

No. A generic applicant must use its own established name and comply with FDA labeling and trademark requirements. It can reference the listed drug through the ANDA pathway without using the CAFCIT brand.

References

1. U.S. Food and Drug Administration. (n.d.). CAFCIT (caffeine citrate) injection and oral solution: Prescribing information. Chiesi USA, Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Electronic Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda/generic-drug-factscrutinizedly